Movatterモバイル変換


[0]ホーム

URL:


MX369022B - Anticuerpos anti-ácido teicoico de la pared celular y conjugados. - Google Patents

Anticuerpos anti-ácido teicoico de la pared celular y conjugados.

Info

Publication number
MX369022B
MX369022BMX2015016405AMX2015016405AMX369022BMX 369022 BMX369022 BMX 369022BMX 2015016405 AMX2015016405 AMX 2015016405AMX 2015016405 AMX2015016405 AMX 2015016405AMX 369022 BMX369022 BMX 369022B
Authority
MX
Mexico
Prior art keywords
conjugates
wall teichoic
antibodies
teichoic antibodies
wall
Prior art date
Application number
MX2015016405A
Other languages
English (en)
Other versions
MX2015016405A (es
Inventor
John Flygare
Richard Vandlen
Sanjeev Mariathasan
John Hiroshi Morisaki
Brown Eric
Darwish Martine
Hazenbos Wouter
Lee Byonung-Chul
M Lehar Sophie
H Pillow Thomas
Staben Leanna
Koefoed Klaus
S Andersen Peter
Strandh Magnus
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/284,609external-prioritypatent/US20140356375A1/en
Priority claimed from PCT/US2014/039113external-prioritypatent/WO2014193722A1/en
Application filed by Genentech IncfiledCriticalGenentech Inc
Publication of MX2015016405ApublicationCriticalpatent/MX2015016405A/es
Publication of MX369022BpublicationCriticalpatent/MX369022B/es

Links

Classifications

Landscapes

Abstract

La presente invención se refiere a anticuerpos anti-ácido teicoico de pared y conjugados antibióticos de ellos, y métodos para su uso.
MX2015016405A2013-05-312014-05-30Anticuerpos anti-ácido teicoico de la pared celular y conjugados.MX369022B (es)

Applications Claiming Priority (5)

Application NumberPriority DateFiling DateTitle
US201361829466P2013-05-312013-05-31
US201361829461P2013-05-312013-05-31
US14/284,609US20140356375A1 (en)2013-05-312014-05-22Anti-wall teichoic antibodies and conjugates
PCT/US2014/039113WO2014193722A1 (en)2013-05-312014-05-22Anti-wall teichoic antibodies and conjugates
PCT/US2014/040324WO2014194247A1 (en)2013-05-312014-05-30Anti-wall teichoic antibodies and conjugates

Publications (2)

Publication NumberPublication Date
MX2015016405A MX2015016405A (es)2016-04-11
MX369022Btrue MX369022B (es)2019-10-25

Family

ID=51989438

Family Applications (2)

Application NumberTitlePriority DateFiling Date
MX2015016405AMX369022B (es)2013-05-312014-05-30Anticuerpos anti-ácido teicoico de la pared celular y conjugados.
MX2019012708AMX2019012708A (es)2013-05-312015-11-27Anticuerpos teicoicos anti-pared y conjugados.

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
MX2019012708AMX2019012708A (es)2013-05-312015-11-27Anticuerpos teicoicos anti-pared y conjugados.

Country Status (30)

CountryLink
EP (2)EP3004162B1 (es)
JP (2)JP6469094B2 (es)
KR (1)KR20160015227A (es)
CN (2)CN112430266A (es)
AU (2)AU2014273939B2 (es)
BR (1)BR112015029838A2 (es)
CA (1)CA2910029A1 (es)
CL (1)CL2015003496A1 (es)
CR (1)CR20150626A (es)
DK (1)DK3004162T3 (es)
EA (1)EA201592078A1 (es)
ES (1)ES2793174T3 (es)
HK (1)HK1220982A1 (es)
HR (1)HRP20200812T1 (es)
HU (1)HUE050451T2 (es)
IL (1)IL242175B (es)
LT (1)LT3004162T (es)
MA (1)MA38686A1 (es)
MX (2)MX369022B (es)
MY (1)MY177774A (es)
PE (1)PE20160715A1 (es)
PH (1)PH12015502636A1 (es)
PL (1)PL3004162T3 (es)
PT (1)PT3004162T (es)
RS (1)RS60256B1 (es)
SG (1)SG11201509839TA (es)
SI (1)SI3004162T1 (es)
UA (1)UA120088C2 (es)
WO (1)WO2014194247A1 (es)
ZA (1)ZA201507977B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2014193722A1 (en)2013-05-312014-12-04Genentech, Inc.Anti-wall teichoic antibodies and conjugates
HK1222577A1 (zh)2013-12-162017-07-07Genentech Inc.擬肽化合物及其抗體藥物偶聯物
JP6895254B2 (ja)2013-12-162021-06-30ジェネンテック, インコーポレイテッドペプチド模倣化合物及びその抗体−薬物コンジュゲート
CN107108694B (zh)2014-09-112022-05-03西雅图基因公司含叔胺药物物质的靶向递送
BR112017011325A2 (pt)2014-12-032020-07-21Genentech, Inc.?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
EP3226909A1 (en)*2014-12-032017-10-11Genentech, Inc.Quaternary amine compounds and antibody-drug conjugates thereof
CA2966211A1 (en)2014-12-032016-06-09Genentech, Inc.Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
CN108064246A (zh)*2015-06-152018-05-22基因泰克公司抗体和免疫结合物
US11793880B2 (en)2015-12-042023-10-24Seagen Inc.Conjugates of quaternized tubulysin compounds
ES2919323T3 (es)2015-12-042022-07-26Seagen IncConjugados de compuestos de tubulisina cuaternizados
AU2017228468B2 (en)*2016-03-042019-12-05Genentech, Inc.Process for the preparation of an antibody-rifamycin conjugate
MA45031A (fr)2016-05-182019-03-27Genmab BvAnticorps et leurs procédés d'utilisation dans le traitement de maladies infectieuses
US10639378B2 (en)2016-06-062020-05-05Genentech, Inc.Silvestrol antibody-drug conjugates and methods of use
SG11202001543XA (en)2017-09-082020-03-30Seattle Genetics IncProcess for the preparation of tubulysins and intermediates thereof
WO2020023871A1 (en)2018-07-272020-01-30Promega CorporationQuinone-containing conjugates
WO2021195716A1 (en)*2020-04-022021-10-07Monash UniversityAntibiotic conjugates
GB202214756D0 (en)*2022-10-072022-11-23Univ Oxford Innovation LtdProduct

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
GB877732A (en)1958-08-121961-09-20Lepetit SpaThe antibiotic rifomycin, its components and methods of preparing same
US3773919A (en)1969-10-231973-11-20Du PontPolylactide-drug mixtures
US4485045A (en)1981-07-061984-11-27Research CorporationSynthetic phosphatidyl cholines useful in forming liposomes
US4867973A (en)*1984-08-311989-09-19Cytogen CorporationAntibody-therapeutic agent conjugates
DD266710A3 (de)1983-06-061989-04-12Ve Forschungszentrum BiotechnologieVerfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en)1983-06-201985-10-01Trustees University Of MassachusettsLiposomes containing modified cholesterol for organ targeting
US4879231A (en)1984-10-301989-11-07Phillips Petroleum CompanyTransformation of yeasts of the genus pichia
US4737456A (en)1985-05-091988-04-12Syntex (U.S.A.) Inc.Reducing interference in ligand-receptor binding assays
US4610919A (en)1985-06-141986-09-09Fiber Bond CorporationBinder for fibrous padding
GB8610600D0 (en)1986-04-301986-06-04Novo Industri AsTransformation of trichoderma
JP2544375B2 (ja)1986-07-141996-10-16鐘淵化学工業株式会社アルキル置換ベンゾキサジノリフアマイシン誘導体
IL85035A0 (en)1987-01-081988-06-30Int Genetic EngPolynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA1304363C (en)1988-11-011992-06-30Takehiko Yamane3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
EP0402226A1 (en)1989-06-061990-12-12Institut National De La Recherche AgronomiqueTransformation vectors for yeast yarrowia
US5013556A (en)1989-10-201991-05-07Liposome Technology, Inc.Liposomes with enhanced circulation time
WO1992022653A1 (en)1991-06-141992-12-23Genentech, Inc.Method for making humanized antibodies
US5362852A (en)1991-09-271994-11-08Pfizer Inc.Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5545721A (en)1992-12-211996-08-13Ophidian Pharmaceuticals, Inc.Conjugates for the prevention and treatment of sepsis
US6660267B1 (en)1992-12-212003-12-09Promega CorporationPrevention and treatment of sepsis
US6214345B1 (en)1993-05-142001-04-10Bristol-Myers Squibb Co.Lysosomal enzyme-cleavable antitumor drug conjugates
US6214388B1 (en)1994-11-092001-04-10The Regents Of The University Of CaliforniaImmunoliposomes that optimize internalization into target cells
US5981522A (en)1995-09-011999-11-09Kaneka CorporationTreatment of disease caused by infection of Helicobacter
JP3963976B2 (ja)1995-12-082007-08-22株式会社カネカクラミジア感染症治療剤
US6322788B1 (en)*1998-08-202001-11-27Stanley Arthur KimAnti-bacterial antibodies and methods of use
EP2270148A3 (en)1999-04-092011-06-08Kyowa Hakko Kirin Co., Ltd.Method for controlling the activity of immunologically functional molecule
JP2003503015A (ja)1999-05-032003-01-28メダレツクス・インコーポレーテツドスタフィロコッカス・アウレウスに対するヒト抗体
CA2388245C (en)1999-10-192012-01-10Tatsuya OgawaThe use of serum-free adapted rat cells for producing heterologous polypeptides
US6946292B2 (en)2000-10-062005-09-20Kyowa Hakko Kogyo Co., Ltd.Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP4290423B2 (ja)2000-10-062009-07-08協和発酵キリン株式会社抗体組成物を生産する細胞
US7064191B2 (en)2000-10-062006-06-20Kyowa Hakko Kogyo Co., Ltd.Process for purifying antibody
US6884869B2 (en)2001-04-302005-04-26Seattle Genetics, Inc.Pentapeptide compounds and uses related thereto
WO2003026577A2 (en)2001-09-242003-04-03Seattle Genetics, Inc.P-amidobenzylethers in drug delivery agents
US7091186B2 (en)2001-09-242006-08-15Seattle Genetics, Inc.p-Amidobenzylethers in drug delivery agents
ATE430580T1 (de)2001-10-252009-05-15Genentech IncGlycoprotein-zusammensetzungen
EP1482972A4 (en)2001-11-202005-11-23Seattle Genetics Inc TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
US20040093621A1 (en)2001-12-252004-05-13Kyowa Hakko Kogyo Co., LtdAntibody composition which specifically binds to CD20
WO2003085119A1 (fr)2002-04-092003-10-16Kyowa Hakko Kogyo Co., Ltd.Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
JPWO2003085118A1 (ja)2002-04-092005-08-11協和醗酵工業株式会社抗体組成物の製造方法
CA2481920A1 (en)2002-04-092003-10-16Kyowa Hakko Kogyo Co., Ltd.Antibody composition-containing medicament
CN104530225A (zh)2002-04-092015-04-22协和发酵麒麟株式会社基因组被修饰的细胞
EP1502603A4 (en)2002-04-092006-12-13Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
DE60336548D1 (de)2002-04-092011-05-12Kyowa Hakko Kirin Co LtdZelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2494104A1 (en)2002-07-312004-04-22Seattle Genetics, Inc.Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP2357006B1 (en)2002-07-312015-09-16Seattle Genetics, Inc.Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7217797B2 (en)2002-10-152007-05-15Pdl Biopharma, Inc.Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2502413A1 (en)2002-11-012004-05-21The Regents Of The University Of Colorado, A Body CorporateQuantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
WO2004050846A2 (en)*2002-12-022004-06-17Biosynexus IncorporatedWall teichoic acid as a target for anti-staphylococcal therapies and vaccines
UA89350C2 (uk)2002-12-162010-01-25Дженентек, Інк.Гуманізоване антитіло, що зв'язує людський cd20
MXPA06002088A (es)2003-08-222006-08-11Activbiotics IncAnalogos de rifamicina y usos de los mismos.
US20080241884A1 (en)2003-10-082008-10-02Kenya ShitaraFused Protein Composition
CA2542125A1 (en)2003-10-092005-04-21Kyowa Hakko Kogyo Co., Ltd.Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
PT1725249E (pt)*2003-11-062014-04-10Seattle Genetics IncCompostos de monometilvalina capazes de conjugação a ligandos
WO2005053742A1 (ja)2003-12-042005-06-16Kyowa Hakko Kogyo Co., Ltd.抗体組成物を含有する医薬
JP2007516291A (ja)2003-12-232007-06-21アクティブバイオティクス インコーポレイティッドリファマイシンアナログおよびその使用法
US7375078B2 (en)2004-02-232008-05-20Genentech, Inc.Heterocyclic self-immolative linkers and conjugates
TR201808537T4 (tr)2004-09-232018-07-23Genentech IncSistein değiştirilmiş antikorlar ve konjugatlar.
EP2722051B1 (en)2005-07-072018-11-07Seattle Genetics, Inc.Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
WO2007008848A2 (en)2005-07-072007-01-18Seattle Genetics, Inc.Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
US8404664B2 (en)*2005-08-112013-03-26Targanta Therapeutics, Inc.Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections
CN101395259A (zh)2005-12-142009-03-25活跃生物药物学有限公司利福霉素类似物及其应用
ES2369946T3 (es)2007-03-012011-12-09Symphogen A/SProcedimiento para clonación de anticuerpos análogos.
EP2144628B1 (en)2007-05-082012-10-17Genentech, Inc.Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
NZ584514A (en)2007-10-192012-07-27Genentech IncCysteine engineered anti-tenb2 antibodies and antibody drug conjugates
CN102089005A (zh)2008-05-122011-06-08斯特罗克斯生物制药有限责任公司金黄色葡萄球菌特异性抗体制剂
US8524691B2 (en)2008-08-132013-09-03The Medicines CompanyPhosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
AU2009302582A1 (en)2008-10-062010-04-15University Of ChicagoCompositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
DK2454284T3 (en)*2009-07-152018-07-02Aimm Therapeutics Bv GRAM POSITIVE BACTERIA-SPECIFIC BINDING COMPOUNDS
CN114246952B (zh)2010-06-082024-11-22基因泰克公司半胱氨酸改造的抗体和偶联物
WO2012113847A1 (en)2011-02-252012-08-30Lonza LtdBranched linker for protein drug conjugates
EP2848257A4 (en)*2012-05-072015-12-02Mogam Biotechnology Inst VACCINE COMPOSITION FOR PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS

Also Published As

Publication numberPublication date
EP3381939A1 (en)2018-10-03
UA120088C2 (uk)2019-10-10
MY177774A (en)2020-09-23
AU2014273939A1 (en)2015-11-26
BR112015029838A2 (pt)2017-09-26
AU2014273939B2 (en)2019-09-19
CR20150626A (es)2016-01-29
CA2910029A1 (en)2014-12-04
PE20160715A1 (es)2016-08-01
PL3004162T3 (pl)2020-07-27
SI3004162T1 (sl)2020-07-31
MA38686A1 (fr)2017-10-31
EP3004162B1 (en)2020-03-11
MX2019012708A (es)2019-12-16
LT3004162T (lt)2020-06-10
JP6469094B2 (ja)2019-02-13
PH12015502636A1 (en)2016-03-07
MX2015016405A (es)2016-04-11
KR20160015227A (ko)2016-02-12
CN105358573B (zh)2020-10-30
IL242175B (en)2020-02-27
AU2019279986A1 (en)2020-01-16
RS60256B1 (sr)2020-06-30
CN105358573A (zh)2016-02-24
ES2793174T3 (es)2020-11-13
JP2016525343A (ja)2016-08-25
JP2019054801A (ja)2019-04-11
CN112430266A (zh)2021-03-02
CL2015003496A1 (es)2016-12-23
EP3004162A1 (en)2016-04-13
HRP20200812T1 (hr)2020-08-07
HK1220982A1 (zh)2017-05-19
ZA201507977B (en)2017-01-25
EA201592078A1 (ru)2016-04-29
WO2014194247A1 (en)2014-12-04
SG11201509839TA (en)2016-01-28
HUE050451T2 (hu)2020-12-28
DK3004162T3 (da)2020-05-18
PT3004162T (pt)2020-05-27

Similar Documents

PublicationPublication DateTitle
MX2019012708A (es)Anticuerpos teicoicos anti-pared y conjugados.
MX369758B (es)Anticuerpos anti-acido teicoico de pared y conjugados.
PH12019501931A1 (en)Anti-pdl1 antibody formulations
MY191169A (en)Anti-fcrh5 antibodies
PH12014502132A1 (en)Anti-lgr5 antibodies and immunoconjugates
PH12015501954A1 (en)Anti-b7-h4 antibodies and immunoconjugates
MX2015012326A (es)Anticuerpos anti-crth2 y su uso.
MX2017007055A (es)Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
PH12014502601A1 (en)ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
TWD170641S (zh)生物感測器腕帶
MX2017003022A (es)Anticuerpos anti-cll-1 e inmunoconjugados.
PH12016501763A1 (en)Multispecific antibodies
CO7151527A2 (es)Anticuerpos anti-cd79 b e inmunoconjugados
MX2015013901A (es)Anticuerpos anti-il-4 y anticuerpos biespecificos y sus usos.
SG10201811017QA (en)Novel antibody frameworks
MX2014002053A (es)Anticuerpos anti -mcsp y metodos de uso.
PH12014501605A1 (en)Anti-lrp5 antibodies and methods of use
MX2017007231A (es)Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
MX2016004853A (es)Metodos de uso de anticuerpos anti-ly6e.
AU357215S (en)Positioning element for construction toy
IN2013MU00848A (es)
AR097668A1 (es)Colorante-polímero
MX2016016233A (es)Anticuerpos anti-lgr5 y sus usos.
MX353951B (es)Anticuerpos de anti-teofilina y metodos de uso.
MX2015010789A (es)Anticuerpos anti-pcsm.

Legal Events

DateCodeTitleDescription
FGGrant or registration

[8]ページ先頭

©2009-2025 Movatter.jp